These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 29774477)

  • 1. Cefepime vs. cefoperazone/sulbactam in combination with amikacin as empirical antibiotic therapy in febrile neutropenia.
    Ponraj M; Dubashi B; Harish BH; Kayal S; Cyriac SL; Pattnaik J; Ranjith K; Pillai US; Jadhav N; Matta KK; Singh J; Jaffa E; Prakash B
    Support Care Cancer; 2018 Nov; 26(11):3899-3908. PubMed ID: 29774477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of piperacillin-tazobactam plus amikacin versus cefoperazone-sulbactam plus amikacin for management of febrile neutropenia in children with lymphoma and solid tumors.
    Demirkaya M; Celebi S; Sevinir B; Hacımustafaoglu M
    Pediatr Hematol Oncol; 2013 Mar; 30(2):141-8. PubMed ID: 23301757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia.
    Karaman S; Vural S; Yildirmak Y; Emecen M; Erdem E; Kebudi R
    Pediatr Blood Cancer; 2012 Apr; 58(4):579-83. PubMed ID: 21674768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.
    Sanz MA; López J; Lahuerta JJ; Rovira M; Batlle M; Pérez C; Vázquez L; Julià A; Palau J; Gutiérrez M; Capote FJ; Ramos F; Benlloch L; Larrea L; Jarque I;
    J Antimicrob Chemother; 2002 Jul; 50(1):79-88. PubMed ID: 12096010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study.
    Le Clech L; Talarmin JP; Couturier MA; Ianotto JC; Nicol C; Le Calloch R; Dos Santos S; Hutin P; Tandé D; Cogulet V; Berthou C; Guillerm G
    Infect Dis (Lond); 2018 Jul; 50(7):539-549. PubMed ID: 29451055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial.
    Gómez L; Estrada C; Gómez I; Márquez M; Estany C; Martí JM; Bastús R; Cirera L; Quintana S; Garau J
    Eur J Clin Microbiol Infect Dis; 2010 Apr; 29(4):417-27. PubMed ID: 20195673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefoperazone-sulbactam for treatment of intra-abdominal infections: results from a randomized, parallel group study in India.
    Chandra A; Dhar P; Dharap S; Goel A; Gupta R; Hardikar JV; Kapoor VK; Mathur AK; Modi P; Narwaria M; Ramesh MK; Ramesh H; Sastry RA; Shah S; Virk S; Sudheer OV; Sreevathsa MR; Varshney S; Kochhar P; Somasundaram S; Desai C; Schou M
    Surg Infect (Larchmt); 2008 Jun; 9(3):367-76. PubMed ID: 18570578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cefepime versus ceftriaxone-amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients.
    Borbolla JR; López-Hernández MA; González-Avante M; DeDiego J; Trueba E; Alvarado ML; Jiménez RM
    Chemotherapy; 2001; 47(5):381-4. PubMed ID: 11561142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
    Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
    Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.
    Pereira CA; Petrilli AS; Carlesse FA; Luisi FA; da Silva KV; de Martino Lee ML
    J Microbiol Immunol Infect; 2009 Apr; 42(2):141-7. PubMed ID: 19597646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
    Charnas R; Lüthi AR; Ruch W
    Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
    Hamidah A; Lim YS; Zulkifli SZ; Zarina AL; Nordiah AJ; Jamal R
    Singapore Med J; 2007 Jul; 48(7):615-9. PubMed ID: 17609821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
    Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
    J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia.
    Montalar J; Segura A; Bosch C; Galan A; Juan O; Molins C; Giner V; Aparicio J
    Med Oncol; 2002; 19(3):161-6. PubMed ID: 12482126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefepime Versus Cefepime Plus Amikacin as an Initial Antibiotic Choice for Pediatric Cancer Patients With Febrile Neutropenia in an Era of Increasing Cefepime Resistance.
    Lee NH; Kang JM; Lee JW; Huh HJ; Lee NY; Yoo KH; Sung KW; Koo HH; Kim YJ
    Pediatr Infect Dis J; 2020 Oct; 39(10):931-936. PubMed ID: 32453199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.
    Jimeno A; Arcediano A; Bazares S; Amador ML; González-Cortijo L; Ciruelos E; Robles L; Castellano D; Paz-Ares L; Lumbreras C; Hornedo J; Cortés-Funes H
    Clin Transl Oncol; 2006 Dec; 8(12):889-95. PubMed ID: 17169762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cefepime-amikacin combination in febrile neutropenic children with malignant hemopathy or tumor].
    Marie-Cardine A; Schneider P; Blot N; Tron P; Vannier JP
    Arch Pediatr; 2003 Apr; 10(4):307-12. PubMed ID: 12818750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost.
    Corapçioglu F; Sarper N
    Pediatr Hematol Oncol; 2005; 22(1):59-70. PubMed ID: 15770833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin.
    Cornely OA; Bethe U; Seifert H; Breuer K; Schütt-Gerowitt H; Salzberger B; Schrappe M; Fätkenheuer G
    Ann Hematol; 2002 Jan; 81(1):37-43. PubMed ID: 11807634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study.
    Erman M; Akova M; Akan H; Korten V; Ferhanoğlu B; Köksal I; Cetinkaya Y; Uzun O; Unal S;
    Scand J Infect Dis; 2001; 33(11):827-31. PubMed ID: 11760163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.